Specific targeting of prostate cancer cells in vitro by the suicide gene/ prodrug system, uracil phosphoribosyltransferase/5-fluorouracil, under the control of prostate-specific membrane antigen promoter/enhancer

Prostate Cancer and Prostatic Diseases

Volumn 12, Issue 2, 2009, Pages 166-171

  Zhao, F J ^a,d   Zhang, S ^b   Yu, Z M ^c   Xia, S J ^a   Li, H ^d  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c MERITER HOSPITAL   (United States)

^d SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; ENHANCED GREEN FLUORESCENT PROTEIN; FLUOROURACIL; PROSTATE SPECIFIC MEMBRANE ANTIGEN; URACIL PHOSPHORIBOSYLTRANSFERASE;

ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CONTROLLED STUDY; ENHANCER REGION; ESCHERICHIA COLI; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; SUICIDE GENE THERAPY;

ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ENHANCER ELEMENTS, GENETIC; ESCHERICHIA COLI; FLOW CYTOMETRY; FLUOROURACIL; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; GLUTAMATE CARBOXYPEPTIDASE II; GREEN FLUORESCENT PROTEINS; HUMANS; MALE; PENTOSYLTRANSFERASES; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 67349221758     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2008.39     Document Type: Article

References (26)

1. Chodak G, Keane T, Klotz L. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 2002; 60: 201-208.
2. Huggins C, Hodges C. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-297.
3. Harzstark A, Ryan C. Novel therapeutic strategies in development for prostate cancer. Expert Opin Investig Drugs 2008; 17: 13-22.
4. Hadaschik B, Gleave M. Therapeutic options for hormone-refractory prostate cancer in 2007. Urol Oncol 2007; 25: 413-419.
5. Mike S, Harrison C, Coles B, Staffurth J, Wilt T, Mason M. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev 2006; 4: CD005247.
6. Swanson G, Faulkner J, Smalley S, Noble M, Stephens R, O'Rourke T et al. Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024. J Urol 2006; 176: 548-553; discussion 553.
7. Longley D, Harkin D, Johnston P. 5-fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-338.
8. Heggie G, Sommadossi J, Cross D, Huster W, Diasio R. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987; 47: 2203-2206.
9. Van Kuilenburg A. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004; 40: 939-950.
10. Moolten F. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-5281.
11. Li J, Huang S, Chen J, Yang Z, Fei X, Zheng M et al. Identification and characterization of human uracil phosphoribosyltransferase (UPRTase). J Hum Genet 2007; 52: 415-422.
12. Kanai F, Kawakami T, Hamada H, Sadata A, Yoshida Y, Tanaka T et al Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res 1998; 58: 1946-1951.
13. Koyama F, Sawada H, Fuji H, Hamada H, Hirao T, Ueno M et al. Adenoviral-mediated transfer of Escherichia coli uracil phosphoribosyltransferase (UPRT) gene to modulate the sensitivity of the human colon cancer cells to 5-fluorouracil. Eur J Cancer 2000; 36: 2403-2410.
14. Oonuma M, Sunamura M, Motoi F, Fukuyama S, Shimamura H, Yamauchi J et al. Gene therapy for intraperitoneally disseminated pancreatic cancers by Escherichia coli uracil phosphoribosiltransferase (UPRT) gene mediated by restricted replication-competent adenoviral vectors. Int J Cancer 2002; 102: 51-59.
15. Miyagi T, Koshida K, Hori O, Kona ka H, Katoh H, Kitagawa Y et al. Gene therapy for prostate cancer using the cytosine deaminase/uracil phosphoribosyltransferase suicide system. J Gene Med 2003; 5 30-37.
16. Ikegami S, Tadakuma T, Ono T, Suzuki S, Yoshimura I, Asano T et al Treatment efficiency of a suicide gene therapy using prostate-specific membrane antigen promoter/enhancer in a castrated mouse model of prostate cancer. Cancer Sci 2004; 95: 367-370.
17. Zhao F, Li H, Cheng H, Zeng H, Wei Q, Li X. (Construction and expression of recombinant plasmid with prostate-specific membrane antigen promoter and enhancer regulating uracil phosphoribosyltransferase gene). Sichuan Da Xue Xue Bao Yi Xue Ban 2005; 36: 172-175.
18. Heidelberger C, Chaudhuri N, Danneberg P, Mooren D, Griesbach L, Duschinsky R et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957; 179: 663-666.
19. Malet-Martino M, Jolimaitre P, Martino R. The prodrugs of 5-fluorouracil. Curr Med Chem Anticancer Agents 2002; 2: 267-310.
20. Baccanari D, Davis S, Knick V, Spector T. 5-Ethynyluracil (776C85): A potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci USA 1993; 90: 11064-11068.
21. Naguib F, Hao S, el Kouni M. Potentiation of 5-fluorouracil efficacy by the dihydrouracil dehydrogenase inhibitor, 5-benzyloxybenzyluracil. Cancer Res 1994; 54: 5166-5170.
22. Schmoll H. Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: Utility in the treatment of advanced colorectal cancer. Anticancer Drugs 2003; 14: 695-702.
23. Niculescu-Duvaz I, Springer C. Introduction to the background, principles, and state of the art in suicide gene therapy. Mol Biotechnol 2005; 30: 71-88.
24. O'Keefe D, Uchida A, Bacich D, Watt F, Martorana A, Molloy P et al Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate 2000; 45: 149-157.
25. Israeli R, Powell C, Corr J, Fair W, Heston W. Expression of the prostate-specific membrane antigen. Cancer Res 1994; 54: 1807-1811.
26. Chang SS, Reuter VE, Heston WD, Gaudin PB. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology 2001; 57: 1179-1183.